Fedratinib

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 276 publications

Managing myelofibrosis in the frailty era: the expanding role of JAK inhibitors.

Managing myelofibrosis in the frailty era: the expanding role of JAK inhibitors.

Journal: Leukemia & lymphoma
Published: April 15, 2026

Management of splenomegaly in patients with myelofibrosis in the era of JAK inhibitors: a comprehensive review.

Management of splenomegaly in patients with myelofibrosis in the era of JAK inhibitors: a comprehensive review.

Journal: Frontiers in oncology
Published: April 09, 2026

SOX10 Overexpression Enhances the Oligodendrocyte Lineage Commitment of iOPCs In Vitro by Reshaping Their Chromatin Binding Landscape.

SOX10 Overexpression Enhances the Oligodendrocyte Lineage Commitment of iOPCs In Vitro by Reshaping Their Chromatin Binding Landscape.

Journal: Bioengineering (Basel, Switzerland)
Published: March 16, 2026

Primary Myelofibrosis (PMF)-The German ONKOPEDIA Guideline 2025.

Primary Myelofibrosis (PMF)-The German ONKOPEDIA Guideline 2025.

Journal: International journal of cancer
Published: February 07, 2026

Integrative In Silico Multi-Omics Profiling of circRNA-Mediated ceRNA Networks Reveals Prognostic Biomarkers and Repurposed Therapeutic Candidates in Gastric Cancer.

Integrative In Silico Multi-Omics Profiling of circRNA-Mediated ceRNA Networks Reveals Prognostic Biomarkers and Repurposed Therapeutic Candidates in Gastric Cancer.

Journal: International journal of molecular sciences
Published: January 23, 2026

Tartrate-Resistant Acid Phosphatase 5 (TRAP/ACP5) aggravates atherosclerosis by regulating macrophage polarization and promoting ferroptosis.

Tartrate-Resistant Acid Phosphatase 5 (TRAP/ACP5) aggravates atherosclerosis by regulating macrophage polarization and promoting ferroptosis.

Journal: Free radical biology & medicine
Published: January 15, 2026

Inhibition of UDP-glucuronosyltransferases by fedratinib, implying a high risk of drug-drug interactions.

Inhibition of UDP-glucuronosyltransferases by fedratinib, implying a high risk of drug-drug interactions.

Journal: Chemico-biological interactions
Published: December 25, 2025

Fedratinib in chronic kidney disease: antifibrotic potential and renal safety signals from integrated network toxicology and pharmacovigilance.

Fedratinib in chronic kidney disease: antifibrotic potential and renal safety signals from integrated network toxicology and pharmacovigilance.

Journal: Renal failure
Published: December 19, 2025

Current treatments, practical management, and emerging investigational therapies for myelofibrosis.

Current treatments, practical management, and emerging investigational therapies for myelofibrosis.

Journal: Expert review of hematology
Published: December 14, 2025

Next-generation Janus kinase inhibitors: Integrating synthetic innovation, structural biology, and computational design for precision drug discovery.

Next-generation Janus kinase inhibitors: Integrating synthetic innovation, structural biology, and computational design for precision drug discovery.

Journal: Pharmaceutical science advances
Published: December 04, 2025

Sodium butyrate induces apoptosis enhanced by JAK2 inhibitor Fedratinib in NK/T-cell lymphoma cell.

Sodium butyrate induces apoptosis enhanced by JAK2 inhibitor Fedratinib in NK/T-cell lymphoma cell.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: November 17, 2025

Post-FDA Approval Experience With Momelotinib in JAK Inhibitor-Naïve Myelofibrosis: Focus on Anemia Response and Treatment-Emergent Nephropathy and Peripheral Neuropathy.

Post-FDA Approval Experience With Momelotinib in JAK Inhibitor-Naïve Myelofibrosis: Focus on Anemia Response and Treatment-Emergent Nephropathy and Peripheral Neuropathy.

Journal: American journal of hematology
Published: October 23, 2025
Showing 1-12 of 276

Last Updated: 06/30/2026